Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexicon Pharmaceuticals

0.5098
+0.00981.96%
Post-market: 0.51000.0002+0.04%19:59 EDT
Volume:2.67M
Turnover:1.36M
Market Cap:184.29M
PE:-0.81
High:0.5262
Open:0.5001
Low:0.4980
Close:0.5000
Loading ...

LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?

Zacks
·
02 Apr

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire
·
02 Apr

Social Buzz: Wallstreetbets Stocks Mixed Premarket Tuesday; Tesla to Advance, Lexicon Pharmaceuticals to Decline

MT Newswires Live
·
01 Apr

US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst

Benzinga
·
31 Mar

BUZZ-U.S. STOCKS ON THE MOVE-GameStop, Oxford Industries, Wolfspeed

Reuters
·
29 Mar

Lexicon Pharmaceuticals Shares up 65% on Licensing Deal With Novo Nordisk for Obesity Drug Candidate

THOMSON REUTERS
·
28 Mar

Lexicon Pharmaceuticals Shares Soar on Novo Nordisk Licensing Deal

Dow Jones
·
28 Mar

BUZZ-Lexicon surges on licensing deal with Novo Nordisk for obesity drug

Reuters
·
28 Mar

Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal

Reuters
·
28 Mar

BRIEF-Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851

Reuters
·
28 Mar

Lexicon Pharmaceuticals Shares up 70% Premarket on Licensing Deal With Novo Nordisk for Obesity Drug Candidate

THOMSON REUTERS
·
28 Mar

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

GlobeNewswire
·
28 Mar

Investors Don't See Light At End Of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Tunnel And Push Stock Down 50%

Simply Wall St.
·
27 Mar

Analysts’ Opinions Are Mixed on These Healthcare Stocks: BridgeBio Pharma (BBIO), Johnson & Johnson (JNJ) and Lexicon Pharmaceuticals (LXRX)

TIPRANKS
·
11 Mar

Lexicon Pharmaceuticals Faces Supply Chain Risks Amidst Changing Trade Policies

TIPRANKS
·
09 Mar

Lexicon Pharmaceuticals’ Mixed Earnings Call: Achievements and Challenges

TIPRANKS
·
08 Mar

Lexicon Pharma Is Maintained at Overweight by Piper Sandler

Dow Jones
·
07 Mar

Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025

GlobeNewswire
·
07 Mar

Lexicon Pharma Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Mar

Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE), Lexicon Pharmaceuticals (LXRX) and Xtant Medical Holdings (XTNT)

TIPRANKS
·
07 Mar